


**Amendments to the Claims:**

1. (Original) A pharmaceutical composition for the treatment of cancer comprising an effective amount of a compound having two gold(I) atoms each covalently bonded to a carbon atom in a covalent link connecting the two gold(I) atoms and a pharmaceutically acceptable excipient.


Claims 2-12. (Cancelled)

13. (Previously Presented) A pharmaceutical composition in accordance with claim 1, wherein said compound has the formula:



where: L and L' are ligands; R' and R'' are substituted or unsubstituted divalent hydrocarbon moieties; a is 0 to 3; b is 0 to 3; R''' is H,  $SO_3^-$ ,  $PO_4^{2-}$ ,  $CO_2H$ , OH,  $(CH_2)_nCH_3$ ,  $O(CH_2)_nCH_3$ ,  $S(CH_2)_nCH_3$ , or  $NR''''C(O)(R''''')$  where  $R''''$  and  $R'''''$  are  $(CH_2)_nCH_3$ ; and n is 0 to 6.

14. (Original) A pharmaceutical composition in accordance with claim 13, wherein said compound has a formula selected from the group consisting of:



Claims 15-19. (Cancelled)

20. (Previously Presented) A pharmaceutical composition in accordance with claim 13, wherein L and L' are independently selected from the group consisting of  $\text{PR}_3$ ,  $\text{P}(\text{OR})_3$ ,  $\text{CNR}$ ,  $\text{NCR}$ ,  $\text{PR}_n(\text{CH}_2\text{OR}^\ddagger)_{3-n}$ ,  $\text{N}_4\text{C}_6\text{H}_{12}$ ,  $[\text{N}_4\text{C}_6\text{H}_{12}-\text{N}-\text{CH}_3]^+$ ,  $\text{PN}_3\text{C}_6\text{H}_{12}$ , and  $\text{P}[\text{N}_3\text{C}_6\text{H}_{12}-\text{N}-\text{CH}_3]^+$ , where R is a substituted or unsubstituted hydrocarbon moiety and  $\text{R}^\ddagger$  is selected from the group consisting of H, Me,  $\text{SO}_2^-$ ,  $\text{PO}_3^-$ , alkyl and aryl, and each  $\text{R}^\ddagger$  in any one ligand is the same or different.

21. (Original) A pharmaceutical composition in accordance with claim 20, wherein R is a substituted or unsubstituted alkyl, alkene, alkyne, aryl or aromatic group and each R in any one ligand is the same or different.
22. (Previously Presented) A pharmaceutical composition in accordance with claim 20, wherein R is selected from the group consisting of methyl, ethyl, propyl, butyl and phenyl groups.
23. (Previously Presented) A pharmaceutical composition in accordance with claim 20, wherein the ligand is  $\text{PPh}_3$ .
24. (Previously Presented) A pharmaceutical composition in accordance with claim 13, wherein  $\text{R}'$  and  $\text{R}''$  are each independently selected from the group consisting of methylene, ethylene, propylene, butylene and phenylene groups.

Claims 25-40. (Cancelled).